Skip to main content

Craig-Hallum Remains a Buy on BioLife Solutions (BLFS)

Tipranks - Tipranks - Wed Nov 5, 2025

Craig-Hallum analyst Matt Hewitt reiterated a Buy rating on BioLife Solutions today. The company’s shares opened today at $27.44.

Meet Your ETF AI Analyst

According to TipRanks, Hewitt is a 2-star analyst with an average return of 0.7% and a 45.13% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Repligen, Alpha Teknova, and Lifecore Biomedical.

BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $31.38.

See the top stocks recommended by analysts >>

BLFS market cap is currently $1.34B and has a P/E ratio of -235.39.

Based on the recent corporate insider activity of 107 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year. Last month, Casdin Partners Master Fund, L.P., a Major Shareholder at BLFS sold 750,000.00 shares for a total of $21,405,000.00.

Read More on BLFS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).